Literature DB >> 11393677

Exercise training causes skeletal muscle venular growth and alters hemodynamic responses in spontaneously hypertensive rats.

S L Amaral1, N P Silveira, T M Zorn, L C Michelini.   

Abstract

OBJECTIVE: To investigate whether training changes skeletal muscle venular profile and hemodynamic responses to exercise we studied spontanesouly hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats submitted to training programme (T = 50-60% of VO2max).
DESIGN: Training (T) was performed on a treadmill over a period of 13 weeks. Age-matched control groups were kept sedentary (S). T and S rats were chronically instrumented for hindlimb flow (HLF) and arterial pressure (AP) measurements at rest, during dynamic exercise and recovery in two different situations: control and after extensive intravenous blockade (hexamethonium + losartan + Nomega-nitro-L-arginine methyl ester + hydralazine). For morphometric analysis, skeletal muscle samples (gracilis) were obtained after transcardiac perfusion with fixative.
RESULTS: T caused a significant reduction of resting mean arterial pressure (MAP) (-11%) only in the SHR group without changing basal HLF. In the sedentary SHR (SHRs), basal relative hindlimb resistance was increased by 45%, but was significantly reduced after T (P < 0.05). During dynamic exercise, MAP increased similarly (10-20 mmHg) in all groups. HLF increases were similar for the four groups up to 0.8 km/h; at higher workloads, HLF was higher in trained SHR (SHRT) versus trained WKY (WKYT) (3.9- versus 2.9-fold increase over basal HLF, respectively). After blockade (and pressure correction with IV phenylephrine infusion), steady-state exercise was performed with similar hindlimb vasodilation in all groups and was accompanied by MAP reduction (-17 +/- 8 mmHg) only in SHRT group. Skeletal muscle venular profile (density, diameter and lumen cross-sectional area) was similar in WKY(T), WKY(S) and SHR(S), but significantly increased in SHR(T). In this group the two-fold increase in venule density was correlated with both the reduction in baseline MAP and the increase in HLF during dynamic exercise.
CONCLUSIONS: The results suggest that increased venule density is a specific adaptation of SHR skeletal muscle to training. Venular growth may contribute to both the pressure-lowering effect and the large HLF at high exercise intensities observed in the trained SHR.

Entities:  

Mesh:

Year:  2001        PMID: 11393677     DOI: 10.1097/00004872-200105000-00014

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Effects of exercise training on pathological cardiac hypertrophy related gene expression and apoptosis.

Authors:  Young I Lee; Joon Y Cho; Mun H Kim; Kee B Kim; Dong J Lee; Kyu S Lee
Journal:  Eur J Appl Physiol       Date:  2006-04-01       Impact factor: 3.078

Review 2.  Exercise-induced neuronal plasticity in central autonomic networks: role in cardiovascular control.

Authors:  Lisete C Michelini; Javier E Stern
Journal:  Exp Physiol       Date:  2009-07-17       Impact factor: 2.969

Review 3.  The NTS and integration of cardiovascular control during exercise in normotensive and hypertensive individuals.

Authors:  Lisete Compagno Michelini
Journal:  Curr Hypertens Rep       Date:  2007-06       Impact factor: 4.592

4.  Endurance exercise effects on cardiac hypertrophy in mice.

Authors:  Gun-Soo Han
Journal:  J Phys Ther Sci       Date:  2014-01-08

5.  Perfusion of Brain Preautonomic Areas in Hypertension: Compensatory Absence of Capillary Rarefaction and Protective Effects of Exercise Training.

Authors:  Maria Tereza Jordão; Alexandre Ceroni; Lisete C Michelini
Journal:  Front Physiol       Date:  2021-12-16       Impact factor: 4.566

6.  Impaired skeletal muscle performance as a consequence of random functional capillary rarefaction can be restored with overload-dependent angiogenesis.

Authors:  Peter G Tickle; Paul W Hendrickse; Hans Degens; Stuart Egginton
Journal:  J Physiol       Date:  2020-02-26       Impact factor: 5.182

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.